Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy (Q41963078)

14 October 2017

Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy (English)

1 reference

14 October 2017

1 reference

10

Akseli Hemminki

1 reference

14 October 2017

9

Anna Kanerva

1 reference

14 October 2017

Joao Manuel Santos

1

1 reference

14 October 2017

Riikka Havunen

2

1 reference

14 October 2017

Mikko Siurala

3

1 reference

14 October 2017

Víctor Cervera-Carrascon

4

1 reference

14 October 2017

Siri Tähtinen

5

1 reference

14 October 2017

Suvi Sorsa

6

1 reference

14 October 2017

Marjukka Anttila

7

1 reference

14 October 2017

Pauliina Karell

8

1 reference

14 October 2017

language of work or name

English

0 references

publication date

14 June 2017

1 reference

International Journal of Cancer

14 October 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

14 October 2017

141

1 reference

14 October 2017

7

1 reference

14 October 2017

1458-1468

1 reference

Emerging Opportunities and Challenges in Cancer Immunotherapy.

14 October 2017

1 reference

Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion

21 January 2018

1 reference

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies

21 January 2018

1 reference

Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients

21 January 2018

1 reference

Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy

21 January 2018

1 reference

Adoptive cell transfer as personalized immunotherapy for human cancer

21 January 2018

1 reference

IL-2: the first effective immunotherapy for human cancer.

21 January 2018

1 reference

Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

21 January 2018

1 reference

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

21 January 2018

1 reference

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

21 January 2018

1 reference

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

21 January 2018

1 reference

Local therapy of cancer with free IL-2.

21 January 2018

1 reference

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

21 January 2018

1 reference

Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma

21 January 2018

1 reference

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

21 January 2018

1 reference

Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma

21 January 2018

1 reference

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

21 January 2018

1 reference

Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients

21 January 2018

1 reference

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

21 January 2018

1 reference

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

21 January 2018

1 reference

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy

21 January 2018

1 reference

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

21 January 2018

1 reference

Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting

21 January 2018

1 reference

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor

21 January 2018

1 reference

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors

21 January 2018

1 reference

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma

21 January 2018

1 reference

Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma

21 January 2018

1 reference

Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir

21 January 2018

1 reference

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.

21 January 2018

1 reference

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors

21 January 2018

1 reference

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice

21 January 2018

1 reference

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

21 January 2018

1 reference

Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation

21 January 2018

1 reference

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

21 January 2018

1 reference

Deregulated TCR alpha beta T cell population provokes extramedullary hematopoiesis in mice deficient in the common gamma chain.

21 January 2018

1 reference

Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.30839

1 reference

14 October 2017

1 reference